Cantex Reviews Potential Prostate Cancer Therapy CX-02 at Recent World Orphan Drug Congress
News
Cantex Pharmaceuticals gave an overview of its lead candidate anti-cancer drug CX-02 at last week’s World Orphan Drug Congress USA in Washington, D.C. Cantex is a clinical-stage biopharma company that develops and markets therapies ... Read more